Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 81 to 90 of 390 total matches.
In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
://medicalletter.org/TML-article-1619e
66
The Medical Letter ® Vol. 63 (1623) May 3, 2021
Medical
Letter Entresto ...
The oral fixed-dose combination of the neprilysin
inhibitor sacubitril and the angiotensin receptor
blocker (ARB) valsartan (Entresto – Novartis) was
approved in 2015 to reduce the risk of cardiovascular
death and hospitalization for heart failure in adults with
chronic heart failure (NYHA Class II-IV) and reduced
ejection fraction (HFrEF; LVEF...
COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
, 2022.
The Medical Letter ® Vol. 64 (1652) June 13, 2022 Spikevax COVID-19 vaccines Comirnaty ...
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
In Brief: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
.
The Medical Letter ® Vol. 65 (1675) May 1, 2023 Kloxxado Narcan opioids opioid abuse opioid dependence ...
The FDA has approved the over-the-counter (OTC)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan nasal
spray has been available by prescription since 2015
for emergency treatment of opioid overdose. Generic
formulations of Narcan have also been approved; the
manufacturers of these products will be required to
switch them to OTC status and amend their labeling
accordingly. Kloxxado, an 8-mg naloxone nasal
spray, remains available only by prescription.
Med Lett Drugs Ther. 2023 May 1;65(1675):72 doi:10.58347/tml.2023.1675e | Show Introduction Hide Introduction
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
Expanded Table: Some Vaccines for Adults online
The Medical Letter ® Vol. 64 (1661) October 17, 2022
162 ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Drugs for Chronic Insomnia
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
of falls.
The Medical Letter ® Vol. 65 (1667) January 9, 2023
2
Benzodiazepine receptor agonists ...
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I alone is not effective,
pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
The Medical Letter ® Vol. 65 (1674) April 17, 2023
58
Table 1. Empiric Treatment of Some Outpatient ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
creatinine
clearance, have been reported with long-term use of
The Medical Letter ® Vol. 66 (1699) April 1 ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
prohibited.
For further information call: 800-211-2769
The Medical Letter ® Vol. 66 (1717) December 9, 2024 ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8 doi:10.58347/tml.2024.1717a | Show Introduction Hide Introduction
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
by methotrexate.
The Medical Letter ® Vol. 63 (1637) November 15, 2021
Table 1. Some Conventional DMARDs ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
completion of therapy.
The Medical Letter ® Vol. 64 (1647) April 4, 2022
50
recommended. PPIs decrease ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.